CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Dr Reddy's Laboratories Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Dr Reddy's Laboratories Ltd
8-2-337,, Road No.3 Banjara Hills
Phone: +91 4049002900p:+91 4049002900 HYDERABAD, 500034  India Ticker: DRREDDYDRREDDY
Business Summary
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Kallam S.Reddy 56 1/1/2022
Co-Chairman of the Board, Managing Director Gunupati V.Prasad 63 8/1/2019 4/8/1986
Chief Executive Officer ErezIsraeli 57 8/1/2019 4/2/2018
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
AURIGENE PHARMACEUTICAL SERVICES LT 39-40, KIADB INDUSTRIAL AREA, BANGALORE IN
Dr. Reddy's Laboratories S.A. Elisabethenanlage 11 Basel Switzerland
OCTOPLUS DEVELOPMENT BV PO BOX 722 LEIDEN NL
5 additional Subsidiary records available in full report.

Business Names
Business Name
500124
Aurigene Discovery Technologies
Aurigene Discovery Technologies (Malaysia) Sdn. Bhd.
123 additional Business Names available in full report.

General Information
Number of Employees: 26,343 (As of 3/31/2024)
Outstanding Shares: 833,046,160 (As of 10/28/2024)
Shareholders: 264,898
Stock Exchange: NSE
Fax Number: +91 4049002999


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, November 21, 2024